Kate has a wealth of experience in Clinical Operations in both Biotechnology companies and Contract Research Organisations. This spans all phases of research with drugs and devices, across a variety of therapeutic indications, in several jurisdictions. She has experience in study design, quality management, building teams, processes and company structure. She participates in ethical review as a Human Research Ethics Committee member and lectures adjunctly in her spare time on commercial research, research ethics and commercialisation of biotechnology. Kate oversees and manages Actinogen’s clinical development operations for Xanamem.
Kate has a Bachelor of Biotechnology innovation (Hons).